Page last updated: 2024-11-04

sulfadimethoxine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Sulfadimethoxine is a long-acting sulfonamide antibiotic used to treat bacterial infections in animals. It is a synthetic compound that acts by inhibiting the synthesis of dihydrofolic acid, an essential coenzyme in bacterial metabolism. Sulfadimethoxine is effective against a wide range of gram-positive and gram-negative bacteria, including Escherichia coli, Salmonella, and Pasteurella. It is commonly used to treat respiratory infections, urinary tract infections, and enteritis in cattle, sheep, swine, poultry, and other animals. The drug is typically administered orally, and it is available in various formulations, including tablets, boluses, and injectable solutions. Sulfadimethoxine is studied extensively to understand its effectiveness, pharmacokinetics, and safety in different animal species. Research is ongoing to investigate potential antimicrobial resistance to sulfadimethoxine and to develop new formulations for improved drug delivery and efficacy.'

Sulfadimethoxine: A sulfanilamide that is used as an anti-infective agent. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

sulfadimethoxine : A sulfonamide consisting of pyrimidine having methoxy substituents at the 2- and 6-positions and a 4-aminobenzenesulfonamido group at the 4-position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5323
CHEMBL ID62193
CHEBI ID32161
SCHEMBL ID93845
MeSH IDM0020742

Synonyms (251)

Synonym
sulfadimethoxydiazine
sulfadimethoxinum
sulfadimetoxina
2,6-dimethoxy-4-sulfanilamidopyrimidine
2,4-dimethoxy-6-sulfanilamido-1,3-diazine
CHEBI:32161 ,
n(1)-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide
sulphadimethoxine
6-sulfanilamido-2,4-dimethoxypyrimidine
2,6-dimethoxy-4-(p-aminobenzenesulfonamido)pyrimidine
MLS001148602
4-amino-n-(2,6-dimethoxypyrimidin-4-yl)benzene-1-sulfonamide
BRD-K71125014-001-07-3
BRD-K71125014-001-05-7
nsc-683544
smr000017367
DIVK1C_000088
KBIO1_000088
4-amino-n-[2,6-bis(methyloxy)pyrimidin-4-yl]benzenesulfonamide
SPECTRUM_001408
IDI1_000088
BPBIO1_000722
PRESTWICK_979
cas-122-11-2
NCGC00016375-01
CBKINASE1_012656
OPREA1_486812
CBKINASE1_000256
nsc683544
sulfadimethoxine
122-11-2
4-amino-n-(2,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide
4-amino-n-(2,6-dimethoxypyrimidin-4-yl)benzenesulfonamide
PRESTWICK2_000728
SPECTRUM5_001221
SMP2_000079
BSPBIO_000656
AB00052219
MLS000103402
MLS000104965
D01142
abcid (tn)
sulfadimethoxine (jan/usp)
agribon (tn)
NCGC00024020-03
NCGC00024020-04
memcozine
diasulfyl
radonin
sulfanilamide, n(sup 1)-(2,6-dimethoxy-4-pyrimidinyl)-
persulfen
madriqid
sulfadimetoxina [inn-spanish]
diasulfa
albon
arnosulfan
neostrepal
dimetazina
sulfadimetossina [italian]
agribon
omnibon
theracanzan
redifal
sulxin
dimethoxysulfadiazine
sulfadimetoxin
n(sup 1)-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide
einecs 204-523-7
benzenesulfonamide, 4-amino-n-(2,6-dimethoxy-4-pyrimidinyl)-
dorisul
deposul
n1-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide
nsc 683544
roscosulf
dinosol
madroxine
metoxidon
4-amino-n-(2,6-dimethoxy-4-pyrimidinyl)benzolsulfonamid
madribon
sulfastop
solfadimetossina [dcit]
madroxin
sudine
scandisil
maxulvet
sulfadimethoxine [jan]
bactrovet
brn 0306856
fuxal
abcid
symbio
sulfadimethoxinum [inn-latin]
sulfadimethoxin
sulfoplan
madrigid
MLS000069720 ,
KBIOGR_000824
KBIOSS_001888
KBIO2_004456
KBIO2_001888
KBIO2_007024
KBIO3_002447
SPBIO_002595
SPECTRUM4_000442
SPECTRUM2_001419
SPBIO_001498
PRESTWICK0_000728
NINDS_000088
SPECTRUM3_001454
PRESTWICK1_000728
SPECTRUM1501144
PRESTWICK3_000728
OPREA1_495206
BSPBIO_002947
NCGC00016375-02
STK018258
HMS2092F21
AC-10998
HMS2090P11
AKOS000485038
DB06150
CHEMBL62193
nsc-757860
HMS500E10
HMS1921J15
HMS1570A18
A804847
HMS2097A18
unii-30cpc5ldex
sulfamed-g
sulfadimethoxine [usp:inn:ban:jan:nf]
5-25-13-00290 (beilstein handbook reference)
ccris 9326
30cpc5ldex ,
[(4-aminophenyl)sulfonyl](2,6-dimethoxypyrimidin-4-yl)amine
pharmakon1600-01501144
nsc757860
tox21_110405
dtxcid303607
dtxsid1023607 ,
sulfadimetossina
solfadimetossina
HMS2230L05
CCG-38972
NCGC00016375-06
NCGC00016375-03
NCGC00016375-04
NCGC00016375-05
FT-0603324
NCGC00016375-10
sulfadimethoxine [green book]
sulfadimethoxine [usp-rs]
sulfadimethoxine [mart.]
sulfadimethoxine [usp monograph]
sulfadimethoxine [inn]
sulfadimethoxine [mi]
sulfadimethoxine [who-dd]
sulfadimethoxine [usp impurity]
EPITOPE ID:122237
S1962
BBL023015
HMS3370K02
AB00052219-15
HY-B0337
SCHEMBL93845
NCGC00016375-09
tox21_110405_1
KS-5335
AB00052219-17
cambridge id 5251398
n(sup1)-(2,6-dimethoxy-4-pyrimidinyl)sulfanilamide
component of rofenaid (salt/mix)
lasibon
sulfadimetoxine
rofenaid (salt/mix)
mecozine
4-sulfa-2,6-dimethoxypyrimidine
2,4-dimethoxy-6-sulfanilamidopyrimidine
sulfabon
2,4-dimethoxy-6-sulfanilamido-1,3-pyrimidine
sdmo
component of prazil (salt/mix)
component of primor (salt/mix)
component of maxutrim (salt/mix)
4-sulfanilamido-2,6-dimethoxypyrimidine
sumbio
6-sulfanilamido-2,4-dimethoxy-1,3-diazine
sulfadimoxine
component of trivalbon (salt/mix)
ultrasulfon
4-(p-aminobenzenesulfonamido)-2,6-dimethoxypyrimidine
sulfanilamide, n1-(2,6-dimethoxy-4-pyrimidinyl)-
suldixine
neostreptal
OPERA_ID_1856
AB00052219_18
AB00052219_19
mfcd00057345
J-004764
sr-01000000227
SR-01000000227-2
sulfadimethoxine, vetranal(tm), analytical standard
sulfadimethoxine, united states pharmacopeia (usp) reference standard
HMS3655H05
sulfadimethoxine, analytical standard, >=98.5% (tlc)
sulfadimethoxine, european pharmacopoeia (ep) reference standard
sulfadimethoxine for peak identification, european pharmacopoeia (ep) reference standard
SR-01000000227-4
SBI-0051656.P002
HMS3714A18
SW149624-4
BCP15413
Q4921678
sulfadimethoxine-13c6
BRD-K71125014-001-17-2
H10770
sulfadimethoxine 1000 microg/ml in acetonitrile
sulfadimethoxine for peak identification
EN300-761486
albon (veterinary)
gtpl12638
Z56763920
sulfadimethoxine (mart.)
bactrovet oral suspension 12.5%
agribon concentrated solution 12.5%, albon concentrated solution 12.5%
sulfasol soluble powder
sulfadimethoxine (usp-rs)
sulfadimethoxine 12.5% oral solution
sulfadimethoxine oral solution
albonbolus
sulfadimethoxine concentrated solution 12.5%
sulfadimethoxine soluble powder
j01ed01
sulfadimethoxine injection 40%
sulfadimethoxine (usp monograph)
sulfadimethoxine solution 12.5%
sulfadimethoxine (usp:inn:ban:jan:nf)
sulfadimetoxina (inn-spanish)
sulfadimethoxinum (inn-latin)
albon or agribon
sulforal
sulfamed
albon oral suspension 5%
medacide-sdm injection 10%
albon tablets
albon s.r. (sustained release)
sulfadimethoxine40%
sulfadimethoxine (usp impurity)
bactrovet tablets 250 mg
di-methox injection 40%
di-methox concentrated solution 12.5%

Research Excerpts

Overview

Sulfadimethoxine (SDM) is an antibiotic often used in combination with ormetoprim to prevent the spread of disease in freshwater aquaculture. It is a widely used sulfonamide veterinary antibiotic and could be a source of agricultural contamination.

ExcerptReferenceRelevance
"Sulfadimethoxine (SDM) is an antibiotic commonly used in concentrated animal feeding operations and released into the environment via manure application on agricultural lands. "( Removal of sulfadimethoxine in soil mediated by extracellular oxidoreductases.
Huang, Q; Sidhu, SS; Singh, R; Zhang, H, 2015
)
2.25
"Sulfadimethoxine (SDM) is an antibiotic often used in combination with ormetoprim to prevent the spread of disease in freshwater aquaculture. "( Photochemical fate of sulfadimethoxine in aquaculture waters.
Chin, YP; Guerard, JJ; Hadad, CM; Mash, H, 2009
)
2.11
"Sulfadimethoxine is a widely used sulfonamide veterinary antibiotic and could be a source of agricultural contamination. "( Sulfadimethoxine degradation kinetics in manure as affected by initial concentration, moisture, and temperature.
Bradford, SA; Wang, QQ; Yates, SR; Zheng, W,
)
3.02

Effects

Sulfadimethoxine (SDM) has been approved by US Food and Drug Administration (FDA) for use in steers and dairy cows with a tolerance of 100 ng/g (ppb) in edible tissues and 10 ppb in milk.

ExcerptReferenceRelevance
"Sulfadimethoxine has a high affinity for plasma protein, and the data were subsequently fitted to a nonlinear model, which included saturable protein binding."( Disposition of sulfadimethoxine in swine: inclusion of protein binding factors in a pharmacokinetic model.
Bevill, RF; Bourne, DW; Dittert, LW; Hayashi, M; Huang, CH; Koritz, GD; Rudawsky, G, 1982
)
1.34
"Sulfadimethoxine (SDM) has been approved by US Food and Drug Administration (FDA) for use in steers and dairy cows with a tolerance of 100 ng/g (ppb) in edible tissues and 10 ppb in milk."( Tissue/fluid correlation study for the depletion of sulfadimethoxine in bovine kidney, liver, plasma, urine, and oral fluid.
Chiesa, OA; Heller, DN; Kijak, PJ; Lancaster, V; Li, H; Li, JX; Smith, ML; Thomas, MH; Von Bredow, J, 2012
)
1.35
"Sulfadimethoxine has a high affinity for plasma protein, and the data were subsequently fitted to a nonlinear model, which included saturable protein binding."( Disposition of sulfadimethoxine in swine: inclusion of protein binding factors in a pharmacokinetic model.
Bevill, RF; Bourne, DW; Dittert, LW; Hayashi, M; Huang, CH; Koritz, GD; Rudawsky, G, 1982
)
1.34

Treatment

ExcerptReferenceRelevance
"Sulfadimethoxine treatment reduced gregarine intensity by 80% to 85% but had no significant effect on gametocyst production, suggesting that sulfonamide toxicity is directed primarily at sporozoites, trophozoites, and perhaps young gamonts."( Efficacy of oral sulfadimethoxine against two gregarine parasites, Protomagalhaensia granulosae and Gregarina cubensis (Apicomplexa: Eugregarinida), infecting the Death's Head cockroach, Blaberus discoidalis.
Clopton, RE; Smith, A, 2002
)
1.38

Toxicity

ExcerptReferenceRelevance
" In the absence of albumin, no cytotoxicity was found at a B(f) of 150 nM whereas in the presence of albumin a similar B(f) resulted in a 40% reduction of viability indicating the importance of total cellular uptake of UCB in eliciting toxic effect."( Cytotoxicity is predicted by unbound and not total bilirubin concentration.
Bellarosa, C; Calligaris, SD; Giraudi, P; Ostrow, JD; Tiribelli, C; Wennberg, RP, 2007
)
0.34

Pharmacokinetics

Sulfadimethoxine had a moderately rapid distribution phase, followed by a slower elimination phase. It had a mean half-life (t 1/2) of 7.

ExcerptReferenceRelevance
" The blood data were described, using a one-compartment pharmacokinetic model."( Pharmacokinetic study of sulfadimethoxine depletion in suckling and growing pigs.
Righter, HF; Showalter, DH; Teske, RH, 1979
)
0.56
" The elimination half-life determined from plasma concentration-time data was approximately 12-5 h, and the volume of distribution was 31-0 per cent of body weight."( Pharmacokinetics of sulphadimethoxine in cattle.
Boxenbaum, HG; Fellig, J; Hanson, LJ; Kaplan, SA; Snyder, WE, 1977
)
0.26
" We conclude that the acetylation capacity for SDM is a factor determining the pharmacokinetic interaction between SDM and ketoprofen in rabbits."( Differential effects of ketoprofen on the pharmacokinetics of sulphadimethoxine in fast and slow acetylator rabbits.
Imamura, Y; Mori, H; Otagiri, M, 1990
)
0.28
" The unbound plasma concentration-time profile was compared with that of the dosage regimen based on nonlinear pharmacokinetics, where a pharmacokinetic model and parameters were used except for the first order absorption rate constant (ka) and bioavailability (F)."( Oral dosage regimen in the nonlinear pharmacokinetics of sulphadimethoxine in pigs.
Hayama, T; Kokue, E; Shimoda, M; Suzuki, R; Vree, TB, 1990
)
0.28
" The pregnant uterus could not be recognised as an extra compartment, either in distribution volume nor in the pharmacokinetic model."( Influence of gestation on the pharmacokinetics of four sulphonamides in goats.
Van Deurzen, JM; Van Duin, CT; Van Gogh, H; Van Miert, AS, 1990
)
0.28
" The agreement between calculated curves of Cf and Ct and the observed values, and relative constancy of pharmacokinetic parameters were obtained over 3 doses."( Nonlinear pharmacokinetics of intravenous sulphadimethoxine and its dosage regimen in pigs.
Hayama, T; Itani, M; Kokue, E; Shimoda, M; Vree, TB, 1989
)
0.28
"The influence of the method used for determination of drugs in biological fluids on the pharmacokinetic parameters of sulphadimethoxine was investigated in healthy adult human subjects."( The comparison of some pharmacokinetic parameters of sulphadimethoxine estimated by high performance liquid chromatography and three spectrophotometric methods.
Klimowicz, A,
)
0.13
" Such changes in pharmacokinetic behavior were not observed in dogs and rats."( Effect of phenylbutazone on serum protein binding and pharmacokinetic behavior of sulfadimethoxine in rabbits, dogs and rats.
Imamura, Y; Nakamura, H; Otagiri, M, 1989
)
0.5
" Results from pharmacokinetic studies indicate a lengthening of the SDM half-life when administration was shifted from single to a multiple dose regime."( A review of the pharmacokinetics and metabolism of sulfadimethoxine in the rainbow trout (Salmo gairdneri).
Kleinow, KM; Lech, JJ, 1988
)
0.53
" Pharmacokinetic analysis of haemolymph concentration-time data indicated that a two compartment model best described sulphadimethoxine disposition, and that there were no apparent sex differences in the lobster."( Pharmacokinetics of sulphadimethoxine in the lobster, Homarus americanus, following intrapericardial administration.
Barron, MG; Gedutis, C; James, MO, 1988
)
0.27
" Modeling these data with a linear pharmacokinetic model gave unsatisfactory fits, and the data were subsequently fitted to a one-compartment model with saturable protein binding."( Disposition of sulfadimethoxine in cattle: inclusion of protein binding factors in a pharmacokinetic model.
Bevill, RF; Bialer, M; Bourne, DW; Dittert, LW; Hayashi, M; Koritz, GD; Rudawsky, G, 1981
)
0.62
" Plasma and urine data were not consistent when a linear pharmacokinetic model was used to describe the data."( Disposition of sulfadimethoxine in swine: inclusion of protein binding factors in a pharmacokinetic model.
Bevill, RF; Bourne, DW; Dittert, LW; Hayashi, M; Huang, CH; Koritz, GD; Rudawsky, G, 1982
)
0.62
" The pharmacokinetic parameters of the sulfonamides as well as their main metabolites (acetyl sulfonamides) were not significantly different in healthy and febrile pigs."( Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs.
Kuiper, HA; Mengelers, MJ; Pijpers, A; Van Gogh, ER; Van Miert, AS; Verheijden, JH, 1995
)
0.61
"Selected pharmacokinetic parameters for sulfadimethoxine and ormetoprim, administered in a 5:1 ratio, via the oral and intraperitoneal (i."( Pharmacokinetics of sulfadimethoxine and ormetoprim in a 5:1 ratio following intraperitoneal and oral administration, in the hybrid striped bass (Morone chrysops x Morone saxitalis).
Bai, SA; Bakal, RS; Stoskopf, MK, 2004
)
0.91

Compound-Compound Interactions

ExcerptReferenceRelevance
" Amoxycillin, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin displaced bilirubin at concentrations much higher than those found clinically."( Displacement of bilirubin from cord serum by sulphadimethoxine, amoxycillin, clavulanic acid in combination with either amoxycillin or ticarcillin, temocillin and cloxacillin.
Davies, BE, 1985
)
0.27
" in combination with 5 mg trimethoprim (TMP) per kg body weight."( Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after intravenous administration to healthy and pneumonic pigs.
Kuiper, HA; Mengelers, MJ; Pijpers, A; Van Gogh, ER; Van Miert, AS; Verheijden, JH, 1995
)
0.61
"The pharmacokinetics were studied of sulfadimethoxine (SDM) or sulfamethoxazole (SMX) in combination with trimethoprim (TMP) administered as a single oral dose (25 mg + 5 mg per kg body weight) to two groups of 6 healthy pigs."( Pharmacokinetics of sulfadimethoxine and sulfamethoxazole in combination with trimethoprim after oral single- and multiple-dose administration to healthy pigs.
Hougee, PE; Huveneers, MB; Kuiper, HA; Mengelers, MJ; Pijpers, A; van Gogh, ER; van Miert, AS; Verheijden, JH, 2001
)
0.91

Bioavailability

ExcerptReferenceRelevance
"50) hours, of the drug, the rate of absorption would have little influence on the dosage regimen."( The bioavailability, dispostion kinetics and dosage of sulphadimethoxine in dogs.
Baggot, JD; Ludden, TM; Powers, TE, 1976
)
0.26
" The absorption rate was independent of the amount of un-ionized drug, which varied with the pH of the solution."( In situ perfusion system for oral mucosal absorption in dogs.
Mizobe, M; Noda, K; Samejima, M; Suzuki, T; Yamahara, H, 1990
)
0.28
" The unbound plasma concentration-time profile was compared with that of the dosage regimen based on nonlinear pharmacokinetics, where a pharmacokinetic model and parameters were used except for the first order absorption rate constant (ka) and bioavailability (F)."( Oral dosage regimen in the nonlinear pharmacokinetics of sulphadimethoxine in pigs.
Hayama, T; Kokue, E; Shimoda, M; Suzuki, R; Vree, TB, 1990
)
0.28
" Peak plasma concentrations of 14C-SDM following oral administration of SDM/OMP were observed at 20 hr with an apparent bioavailability of 38%."( Influence of ormetoprim on the bioavailability, distribution, and pharmacokinetics of sulfadimethoxine in rainbow trout (Oncorhynchus mykiss).
Droy, BF; Kleinow, KM; Lech, JJ; Tate, T, 1989
)
0.5
" The systemic bioavailability was 19."( Kinetic disposition, systemic bioavailability, tissue levels and acetylation of some sulphonamides in goats.
Atef, M; Issa, M; Ramadan, A; Youssef, SA,
)
0.13
" Lower relative bioavailability values were evident with crystalline SDM and with high doses of the sodium salt."( A review of the pharmacokinetics and metabolism of sulfadimethoxine in the rainbow trout (Salmo gairdneri).
Kleinow, KM; Lech, JJ, 1988
)
0.53
" Oral bioavailability at the 42-mg/kg dose, calculated from the area under the haemolymph concentration-time curve (AUC) relative to the AUC from intravascular administration, was between 47 and 52% for single or multiple doses of the free drug."( Oral bioavailability and disposition of sulphadimethoxine in lobster, Homarus americanus, following single and multiple dosing regimens.
Barron, MG; James, MO, 1994
)
0.29
" Oral bioavailability was 52."( Disposition of sulfadimethoxine in male llamas (Llama glama) after single intravenous and oral administrations.
Boothe, DM; Chatfield, J; Herzog, T; Jensen, J; Junkins, K, 2003
)
0.67
" Oral bioavailability was 103% +/- 38%."( Disposition of sulfadimethoxine in camels (Camelus dromedarius) following single intravenous and oral doses.
Boothe, D; Chatfield, J; Herzog, T; Jensen, J; Junkins, K, 2001
)
0.66
"Adsorption and desorption are important processes that influence the transport, transformation and bioavailability of antimicrobials in soils."( Sorption and desorption of sulfadimethoxine, sulfaquinoxaline and sulfamethazine antimicrobials in Brazilian soils.
Doretto, KM; Peruchi, LM; Rath, S, 2014
)
0.7
" than in the gavage group, and the area under the curve (AUC) value for relative bioavailability following gavage administration was 25."( Sulfadimethoxine in giant freshwater prawns (Macrobrachium rosenbergii): an attempt to estimate the withdrawal time by a population pharmacokinetic approach.
Giorgi, M; Imsilp, K; Klangkaew, N; Poapolathep, A; Poapolathep, S; Sakulthaew, C; Toutain, PL; Wannapat, N, 2017
)
1.9
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
" The results showed that sulfadimethoxine is well absorbed and accumulates in the muscle, kidneys and liver, where concentrations were higher than the maximum residue limits (MRLs) authorised in EU legislation."( Validation of a LC-MS/MS method for the quantitative analysis of four antibiotics in pig tissues and plasma to assess the risk of transfer of residues to edible matrices after exposure to cross-contaminated feed.
Gaugain, M; Hurtaud-Pessel, D; Lagree, MP; Laurentie, M; Perrin-Guyomard, A; Sanders, P; Santos-Santórum Suárez, C; Taillandier, JF; Viel, A, 2022
)
1.02

Dosage Studied

Sulfadimethoxine (SDM) blood clearance, gastrointestinal absorption and tissue distribution and elimination were determined in channel catfish (Ictalurus punctatus) after intravenous and oral dosing using radiolabelled SDM. A reevaluation of the disposition kinetics and extent of absorption of sulfadimethyloxine in normal dogs was carried out.

ExcerptRelevanceReference
"Sulfadimethoxine was administered (IV) to suckling pigs (1 to 2 weeks old) and to growing pigs (11 to 12 weeks old) at a dosage of 55 mg/kg of body weight (single dose)."( Pharmacokinetic study of sulfadimethoxine depletion in suckling and growing pigs.
Righter, HF; Showalter, DH; Teske, RH, 1979
)
2.01
" A satisfactory dosage regimen might consist of a priming dose (55 mg/kg) and maintenance dosage (27."( Pharmacokinetics of sulfadimethoxine in cats.
Baggot, JD, 1977
)
0.58
"A reevaluation of the disposition kinetics and extent of absorption of sulfadimethoxine in normal dogs following intravenous and oral dosage has been made."( Bioavailability, disposition kinetics and dosage of sulfadimethoxine in dogs--a correction.
Baggot, JD; Sams, RA, 1977
)
0.74
"50) hours, of the drug, the rate of absorption would have little influence on the dosage regimen."( The bioavailability, dispostion kinetics and dosage of sulphadimethoxine in dogs.
Baggot, JD; Ludden, TM; Powers, TE, 1976
)
0.26
"An oral high dosage regimen of sulphadimethoxine (SDM) was examined in pigs."( Oral dosage regimen in the nonlinear pharmacokinetics of sulphadimethoxine in pigs.
Hayama, T; Kokue, E; Shimoda, M; Suzuki, R; Vree, TB, 1990
)
0.28
" dose of SDM was based on the dosage regimen using the nonlinear pharmacokinetic model (50 mg/kg, 24 hour interval, 4 days)."( Nonlinear pharmacokinetics of intravenous sulphadimethoxine and its dosage regimen in pigs.
Hayama, T; Itani, M; Kokue, E; Shimoda, M; Vree, TB, 1989
)
0.28
"The pharmacokinetics of sulfadimethoxine (SDM) blood clearance, gastrointestinal absorption and tissue distribution and elimination were determined in channel catfish (Ictalurus punctatus) after intravenous and oral dosing using radiolabelled SDM."( Sulfadimethoxine pharmacokinetics and metabolism in the channel catfish (Ictalurus punctatus).
Michel, CM; O'Connor, JM; Squibb, KS; Zelikoff, JT, 1988
)
2.02
" This disease model offers potential for use in pharmacokinetic and target tissue drug concentration studies and for dosage titration of drugs intended for treatment of bacterial pneumonias."( Characterization of a Pasteurella multocida (serotype B) bovine pneumonic pasteurellosis model and the effect of antimicrobials during peracute infection.
April, M; Carnevale, RA; Furrow, RD; Gaines, SA; Guarnieri, JA; McRae, DT; Parbuoni, EL, 1986
)
0.27
"0 mg/kg/day (10 rats per dosage and drug)."( Monodrug efficacies of sulfonamides in prophylaxis for Pneumocystis carinii pneumonia.
Hughes, WT; Killmar, J, 1996
)
0.29
" Urine and faeces were collected from 0 to 72 h after dosing and tissue samples were collected from animals exsanguinated at 12, 24, 48 and 72 h after dosing."( Metabolism of 14C-sulphadimethoxane in swine.
Adams, PE; Feil, VJ; Paulson, GD, 1996
)
0.29
" dosing (58."( Disposition of sulfadimethoxine in male llamas (Llama glama) after single intravenous and oral administrations.
Boothe, DM; Chatfield, J; Herzog, T; Jensen, J; Junkins, K, 2003
)
0.67
"Single-dose pharmacokinetics of sulfadimethoxine were determined in six adult camels (Camelus dromedarius) following administration of a mean dosage of 17."( Disposition of sulfadimethoxine in camels (Camelus dromedarius) following single intravenous and oral doses.
Boothe, D; Chatfield, J; Herzog, T; Jensen, J; Junkins, K, 2001
)
0.95
" Sulfamethoxazole and trimethoprim show good dose-response relationships."( [Effects of antimicrobial drugs on soil microbial respiration].
Li, X; Liu, F; Su, HC; Tao, R; Ying, GG; Zhou, QX, 2009
)
0.35
" The physicochemical properties of SAs, dosage and nature of the matrix are the factors mainly responsible for their distribution in the natural environment."( Sulfadimethoxine and sulfaguanidine: their sorption potential on natural soils.
Białk-Bielińska, A; Bielawska, A; Kołodziejska, M; Kumirska, J; Maszkowska, J; Mrozik, W; Palavinskas, R; Stepnowski, P, 2012
)
1.82
"At peak postnatal hyperbilirubinemia, j/j Gunn rat pups were dosed with sulfadimethoxine to induce bilirubin encephalopathy."( Lipid peroxidation is not the primary mechanism of bilirubin-induced neurologic dysfunction in jaundiced Gunn rat pups.
Daood, MJ; Hoyson, M; Watchko, JF, 2012
)
0.61
") or gavage administration at a dosage of 50 mg/kg body weight (b."( Sulfadimethoxine in giant freshwater prawns (Macrobrachium rosenbergii): an attempt to estimate the withdrawal time by a population pharmacokinetic approach.
Giorgi, M; Imsilp, K; Klangkaew, N; Poapolathep, A; Poapolathep, S; Sakulthaew, C; Toutain, PL; Wannapat, N, 2017
)
1.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (5)

RoleDescription
antiinfective agentA substance used in the prophylaxis or therapy of infectious diseases.
antimicrobial agentA substance that kills or slows the growth of microorganisms, including bacteria, viruses, fungi and protozoans.
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
drug allergenAny drug which causes the onset of an allergic reaction.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
pyrimidinesAny compound having a pyrimidine as part of its structure.
sulfonamideAn amide of a sulfonic acid RS(=O)2NR'2.
substituted aniline
aromatic etherAny ether in which the oxygen is attached to at least one aryl substituent.
sulfonamide antibioticA class of sulfonamides whose members generally have bacteriostatic antibiotic properties.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (35)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, CruzipainTrypanosoma cruziPotency6.30960.002014.677939.8107AID1476
glp-1 receptor, partialHomo sapiens (human)Potency19.95260.01846.806014.1254AID624417
thioredoxin reductaseRattus norvegicus (Norway rat)Potency5.01190.100020.879379.4328AID588453
USP1 protein, partialHomo sapiens (human)Potency89.12510.031637.5844354.8130AID743255
TDP1 proteinHomo sapiens (human)Potency2.85710.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency33.49150.000714.592883.7951AID1259369; AID1259392
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency4.46680.011212.4002100.0000AID1030
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.49150.001530.607315,848.9004AID1224848; AID1224849
estrogen nuclear receptor alphaHomo sapiens (human)Potency10.72340.000229.305416,493.5996AID743091
transcriptional regulator ERG isoform 3Homo sapiens (human)Potency4.46680.794321.275750.1187AID624246
gemininHomo sapiens (human)Potency35.48130.004611.374133.4983AID624297
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency39.81070.031610.279239.8107AID884; AID885
lethal factor (plasmid)Bacillus anthracis str. A2012Potency0.25120.020010.786931.6228AID912
lamin isoform A-delta10Homo sapiens (human)Potency0.00180.891312.067628.1838AID1487
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Polyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)Potency31.62280.316212.765731.6228AID881
Rap guanine nucleotide exchange factor 3Homo sapiens (human)Potency31.62286.309660.2008112.2020AID720707
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency31.62280.00638.235039.8107AID881
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency39.81071.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)1,000.00000.11007.190310.0000AID1449628
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)1.33900.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.62200.00020.522910.0000AID625221
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (69)

Processvia Protein(s)Taxonomy
lipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
phospholipid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
apoptotic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell population proliferationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of macrophage derived foam cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell migrationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
prostate gland developmentPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
regulation of epithelial cell differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of chemokine productionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of peroxisome proliferator activated receptor signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
positive regulation of keratinocyte differentiationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of cell cyclePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
negative regulation of growthPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
hepoxilin biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
endocannabinoid signaling pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cannabinoid biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxin A4 biosynthetic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleic acid metabolic processPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid oxidationPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipoxygenase pathwayPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
adaptive immune responseRap guanine nucleotide exchange factor 3Homo sapiens (human)
signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayRap guanine nucleotide exchange factor 3Homo sapiens (human)
associative learningRap guanine nucleotide exchange factor 3Homo sapiens (human)
Rap protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of actin cytoskeleton organizationRap guanine nucleotide exchange factor 3Homo sapiens (human)
negative regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
intracellular signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of GTPase activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of angiogenesisRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of protein export from nucleusRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of stress fiber assemblyRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
positive regulation of syncytium formation by plasma membrane fusionRap guanine nucleotide exchange factor 3Homo sapiens (human)
establishment of endothelial barrierRap guanine nucleotide exchange factor 3Homo sapiens (human)
cellular response to cAMPRap guanine nucleotide exchange factor 3Homo sapiens (human)
Ras protein signal transductionRap guanine nucleotide exchange factor 3Homo sapiens (human)
regulation of insulin secretionRap guanine nucleotide exchange factor 3Homo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (21)

Processvia Protein(s)Taxonomy
iron ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
calcium ion bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
lipid bindingPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 13S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 8(S)-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
arachidonate 15-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
linoleate 9S-lipoxygenase activityPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
guanyl-nucleotide exchange factor activityRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
protein domain specific bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
cAMP bindingRap guanine nucleotide exchange factor 3Homo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (25)

Processvia Protein(s)Taxonomy
nucleusPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytosolPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
cytoskeletonPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
plasma membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
adherens junctionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
focal adhesionPolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
membranePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
extracellular exosomePolyunsaturated fatty acid lipoxygenase ALOX15BHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
cortical actin cytoskeletonRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
microvillusRap guanine nucleotide exchange factor 3Homo sapiens (human)
endomembrane systemRap guanine nucleotide exchange factor 3Homo sapiens (human)
membraneRap guanine nucleotide exchange factor 3Homo sapiens (human)
lamellipodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
filopodiumRap guanine nucleotide exchange factor 3Homo sapiens (human)
extracellular exosomeRap guanine nucleotide exchange factor 3Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (100)

Assay IDTitleYearJournalArticle
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588461High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588459High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, Validation compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588460High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, Validation Compound Set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID584116Ratio of MIC for Escherichia coli KAM32 harboring cloned pSP72 lmrS to MIC for Escherichia coli KAM32 harboring pSP722010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID346025Binding affinity to beta cyclodextrin2009Bioorganic & medicinal chemistry, Jan-15, Volume: 17, Issue:2
Convenient QSAR model for predicting the complexation of structurally diverse compounds with beta-cyclodextrins.
AID310931Partition coefficient, log P of the compound2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID389363Inhibition of beta-hematin formation assessed as drug: hematin molar ratio causing inhibition of hem polymerization after 24 hrs by HPIA method2008Bioorganic & medicinal chemistry, Oct-15, Volume: 16, Issue:20
New ferrocenic pyrrolo[1,2-a]quinoxaline derivatives: synthesis, and in vitro antimalarial activity.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID310933Permeability across PAMPA membrane after 7 hrs2007Journal of medicinal chemistry, Feb-22, Volume: 50, Issue:4
In silico and in vitro filters for the fast estimation of skin permeation and distribution of new chemical entities.
AID33557The ability concentration.)2000Journal of medicinal chemistry, May-18, Volume: 43, Issue:10
Biosensor analysis of the interaction between immobilized human serum albumin and drug compounds for prediction of human serum albumin binding levels.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID624608Specific activity of expressed human recombinant UGT1A42000Annual review of pharmacology and toxicology, , Volume: 40Human UDP-glucuronosyltransferases: metabolism, expression, and disease.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID584115Antibacterial activity against Escherichia coli KAM32 harboring pSP72 by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID55867Inhibition of Escherichia coli (K12J53) Dihydopteroate synthase.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID25817PKa value was measured1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID584114Antibacterial activity against Escherichia coli KAM32 harboring Staphylococcus aureus cloned pSP72 lmrS by broth microdilution method2010Antimicrobial agents and chemotherapy, Dec, Volume: 54, Issue:12
LmrS is a multidrug efflux pump of the major facilitator superfamily from Staphylococcus aureus.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID55868In vitro inhibition of Escherichia coli (K12J53) growth.1981Journal of medicinal chemistry, Apr, Volume: 24, Issue:4
Structure-activity relationships in dihydropteroate synthase inhibition by sulfanilamides. Comparison with the antibacterial activity.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159537qHTS screening for TAG (triacylglycerol) accumulators in algae2017Plant physiology, Aug, Volume: 174, Issue:4
Identification and Metabolite Profiling of Chemical Activators of Lipid Accumulation in Green Algae.
AID1224864HCS microscopy assay (F508del-CFTR)2016PloS one, , Volume: 11, Issue:10
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (714)

TimeframeStudies, This Drug (%)All Drugs %
pre-1990453 (63.45)18.7374
1990's69 (9.66)18.2507
2000's71 (9.94)29.6817
2010's91 (12.75)24.3611
2020's30 (4.20)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.01

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.01 (24.57)
Research Supply Index6.69 (2.92)
Research Growth Index4.49 (4.65)
Search Engine Demand Index96.92 (26.88)
Search Engine Supply Index3.79 (0.95)

This Compound (34.01)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials13 (1.64%)5.53%
Reviews17 (2.14%)6.00%
Case Studies22 (2.77%)4.05%
Observational0 (0.00%)0.25%
Other741 (93.44%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]